Logan Mendheim
Psychiatric/Mental Health · Helena, ALNPI 1871042226
Payments from drug & device makers
Across 569 payments — averaging $18.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$2K
- AbbVie$1K
- Vanda Pharmaceuticals Inc.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$931
- Takeda Pharmaceuticals U.S.A., Inc.$817
- Axsome Therapeutics, Inc.$685
- plus $4K from 23 others
What the payments were for
- Food & beverage$10,427100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 67 | $1,639 |
| AbbVie | 121 | $1,357 |
| Vanda Pharmaceuticals Inc. | 47 | $1,015 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 45 | $931 |
| Takeda Pharmaceuticals U.S.A., Inc. | 41 | $817 |
| Axsome Therapeutics, Inc. | 28 | $685 |
| Otsuka America Pharmaceutical, Inc. | 32 | $644 |
| Alkermes, Inc. | 39 | $637 |
| Teva Pharmaceuticals USA, Inc. | 30 | $514 |
| Lundbeck LLC | 18 | $425 |
| Sunovion Pharmaceuticals Inc. | 13 | $247 |
| Supernus Pharmaceuticals, Inc. | 19 | $232 |
| Almatica Pharma LLC | 11 | $231 |
| Neurocrine Biosciences, Inc. | 12 | $221 |
| Corium, LLC | 8 | $166 |
| Neos Therapeutics, LP | 8 | $153 |
| Avanir Pharmaceuticals, Inc. | 7 | $133 |
| Bausch Health US, LLC | 4 | $81 |
| Eisai Inc. | 4 | $63 |
| Indivior Inc. | 3 | $57 |
| Noven Therapeutics, LLC | 3 | $51 |
| Adlon Therapeutics L.p. | 2 | $25 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $16 |
| Alfasigma USA, Inc. | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Brainsway USA Inc | 1 | $15 |
| Tris Pharma Inc | 1 | $13 |
| AstraZeneca | 1 | $13 |
How this compares
$10,427 in reported general payments places this provider in the 90th percentile of 378 psychiatric/mental health providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 19 | $61,524 |
| RexultiBrexpiprazole | 24 | $52,097 |
| LybalviOlanzapine/Samidorphan Malate | 25 | $43,064 |
| VraylarCariprazine Hcl | 25 | $40,868 |
| CaplytaLumateperone Tosylate | 13 | $21,721 |
| Aripiprazole | 92 | $6,841 |
| Doxepin Hcl | 112 | $4,964 |
| Trazodone Hcl | 131 | $4,806 |
| Clomipramine Hcl | 16 | $4,615 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 55 | $4,461 |
| Bupropion XlBupropion Hcl | 146 | $4,378 |
| Buspirone Hcl | 128 | $3,596 |
| Divalproex Sodium ErDivalproex Sodium | 36 | $3,528 |
| Asenapine Maleate | 14 | $3,502 |
| Quetiapine Fumarate | 107 | $2,871 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $1,639 | $61,52419 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $644 | $52,09724 claims |
| Alkermes, Inc.Lybalvi | $637 | $43,06425 claims |
| AbbVieVraylar | $1,357 | $40,86825 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $931 | $21,72113 claims |
| Almatica Pharma LLCSertraline Hcl | $231 | $63171 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 378 psychiatric/mental health providers in Alabama.
Other psychiatric/mental health in Helena
- Anthony PhillipsHelena$15K
- Robert CrowellHelena$9K
- Laura GrahamMontgomery$80K
- Yuliya SpencerBirmingham$65K
- Keri BarrBay Minette$35K
- John HayesMobile$30K
- Logan ThrasherHoover$22K
- Ian KinzerHuntsville$15K
- Latisha AliHoover$15K
- Taylor BarrettGadsden$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.